Targets › THPO
6 programs from 6 companies in 7 trials: 3 Phase 1, 2 Phase 2, 2 Phase 3; Hematology, Other; next expected readout Jan 2028.
Lineage-specific cytokine affecting the proliferation and maturation of megakaryocytes from their committed progenitor cells. It acts at a late stage of megakaryocyte development. (UniProt, P40225)
Open in Phaseline: the race on THPO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Geropharm | GP40141 Thrombopoietin receptor agonist | THPO | Phase 3 | Drug Effect | Mar 2028 |
| MIBIO PTE. | rhTPO Recombinant human thrombopoietin (TPO) receptor agonist | THPO | Phase 3 | Thrombocytopenia Associated With Chronic Liver Disease | Oct 2028 |
| The First Affiliated Hospital of Soochow University | Recombinant Human Thrombopoietin Recombinant thrombopoietin cytokine that binds to and activates the TPO receptor on megaka | THPO | Phase 2 | MDS (Myelodysplastic Syndrome) | Jan 2028 |
| Anhui Provincial Hospital | Recombinant human thrombopoietin Thrombopoietin (TPO) analog | THPO | Phase 2 | Thrombocytopenia | – |
| Chongqing Peg-Bio Biopharm | PN20 thrombopoietin receptor agonist | THPO | Phase 1 | Primary Immune Thrombocytopenia (ITP); Thrombocytopenia Associated With Chronic Liver Disease | – |
| Sichuan Clover Biopharmaceuticals | SCB-219M TNF receptor II-Fc fusion protein with TPO mimetic peptide | TNFRSF1B, THPO | Phase 1 | Chemotherapy-induced Thrombocytopenia (CIT) | – |
Thrombocytopenia Associated With Chronic Liver Disease (2) MDS (Myelodysplastic Syndrome) (1) Drug Effect (1) Thrombocytopenia (1) Chemotherapy-induced Thrombocytopenia (CIT) (1) Primary Immune Thrombocytopenia (ITP) (1)
small molecule (5), protein or peptide (1)
The First Affiliated Hospital of Soochow University (1) Geropharm (1) MIBIO PTE. (1) Anhui Provincial Hospital (1) Sichuan Clover Biopharmaceuticals (1) Chongqing Peg-Bio Biopharm (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.